PDF factsheet
      Z

cholesterol lowering intervention in cardiovascular prevention for women, clinical trials results

Atorvastatin versus placebo
ASCOT (women subgroup) , 2003
Atorvastatin 10 mg daily
versus
placebo
hypertensive patients (aged 40-79 years with at least three other cardiovascular risk factors) - subgroup of womendouble-blind
Follow-up duration: 3.3 y
Europe
Lovastatin versus placebo
AFCAPS (women subgroup) , 1998
Lovastatin 20–40 mg daily
versus
placebo
men and postmenopausal women without clinical evidence of cardiovascular disease (CVD) who had average low-density lipoprotein cholesterol and below average high-density lipoprotein cholesterol - subgroup of womendouble blind
Follow-up duration: 5.2 y
US
Pravastatin versus placebo
ALLHAT (women subgroup) , 2002
Pravastatin 40 mg daily
versus
control
Ambulatory persons, aged 55 years or older, with low-density lipoprotein cholesterol (LDL-C) of 120 to 189 mg/dL (100 to 129 mg/dL if known CHD) and triglycerides lower than 350 mg/dL- subgroup of womenopen
Follow-up duration: 4.8 y
US
MEGA (women subgroup) , 2006
Pravastatin 10–20 mg daily
versus
control
patients with hypercholesterolaemia (total cholesterol 5.69-6.98 mmol/L) and no history of coronary heart disease or stroke- subgroup of womenopen
Follow-up duration: 5.3 y
Japan
Rosuvastatin versus placebo
JUPITER (women subgroup) , 2008
Rosuvastatin 20 mg daily
versus
placebo
apparently healthy men and women with low-density lipoprotein cholesterol levels of less than 130 mg/dL and high-sensitivity C-reactive protein levels of 2.0 mg/L or higher - subgroup of womendouble-blind
Follow-up duration: 1.9 y
26 countries
Simvastatin versus placebo
HPS (women subgroup) , 2002
Simvastatin 40 mg
versus
placebo
UK adults (aged 40-80 years) with coronary disease,other occlusive arterial disease, or diabetes - subgroup of women without CHDdouble blind
Follow-up duration: 5 y
UK

  Options


in first

in second

  Filter